ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$63.93 USD
+0.58 (0.92%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $63.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
ANI Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ANIP 63.93 +0.58(0.92%)
Will ANIP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Other News for ANIP
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 ...
ANIP Faces Setback in Legal Dispute Over Royalties
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value
Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment
ANI Pharmaceuticals (ANIP) Shares Drop Following Clinical Trial Results